Carbonic anhydrase-9 expression in head and neck cancer: a meta-analysis.
The purpose of the study was to compare CA-9 positivity versus CA-9 negativity in head and neck malignancies and to correlate levels of CA-9 with tumor grade, size, and nodal status. Overall and disease-free survival were also compared for CA-9 positive and negative tumors. A literature search was performed using Medline, Embase, Ovid and Cochrane databases for studies between 1990 and 2009. Carbonic anhydrase IX, CA IX, CA-9, head and neck, and survival were used as search terms. Random-effect meta-analytical techniques were conducted for outcome measures of overall survival and disease-free survival. Sixteen studies matched the selection criteria, reporting on 1,470 patients. Eight hundred and forty two specimens were reported as being CA-9 positive or negative: 512 (60.81%) were CA-9 positive and 330 (39.19%) were CA-9 negative. Nine hundred and eighty specimens had levels of CA-9 expression recorded: 547 (55.82%) had high levels of CA-9 and 433 (44.18%) had low CA-9 levels. Survival was significantly reduced if the tumor was positive for CA-9 (P < 0.0001). Disease-free survival is significantly reduced in patients with CA-9 positive (P = 0.0008) head and neck malignant tumors. The presence of CA-9 in head and neck malignant tumors is associated with reduced overall survival and disease-free survival.
Department of Otolaryngology Head and Neck Surgery, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK. peridis@gmail.com
Stamatios
S
Peridis
Gemma
G
Pilgrim
Ioannis
I
Athanasopoulos
Konstantinos
K
Parpounas
D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000032:analysis*; D018572:Disease-Free Survival; D006258:Head and Neck Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis; D015609:Organotechnetium Compounds; D010091:Oximes; D012680:Sensitivity and Specificity; D015996:Survival Rate
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015609:Organotechnetium Compounds; D010091:Oximes; C105527:technetium Tc 99m 4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases
J Clin Oncol. 2001 Aug 15;19(16):3660-8
11504747
Int J Radiat Biol. 2008 Jan;84(1):47-52
17852557
Jpn J Clin Oncol. 2008 Jun;38(6):402-7
18573850
Cancer Res. 2001 Nov 1;61(21):7992-8
11691824
Clin Cancer Res. 2005 Jan 1;11(1):97-106
15671533
Radiother Oncol. 2007 Jun;83(3):383-8
17543403
Head Neck. 2007 Jun;29(6):591-604
17252597
J Urol. 2004 Jun;171(6 Pt 1):2461-6
15126876
Clin Cancer Res. 2003 Nov 15;9(15):5666-74
14654550
J Natl Cancer Inst. 1959 Apr;22(4):719-48
13655060
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Histopathology. 2005 Jun;46(6):668-76
15910598
Histopathology. 2006 Dec;49(6):594-602
17163844
Oral Oncol. 2009 Jan;45(1):63-8
18620902
J Clin Oncol. 2003 Feb 1;21(3):473-82
12560438
Hum Pathol. 2008 Sep;39(9):1317-22
18440050
Clin Cancer Res. 2003 Feb;9(2):802-11
12576453
Ann Thorac Surg. 2004 Feb;77(2):745-53
14759484
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7
17056190
Clin Cancer Res. 2005 Nov 1;11(21):7614-20
16278379
J Clin Oncol. 2006 Feb 10;24(5):727-35
16418497
Pathol Res Pract. 2009;205(1):1-9
19008051
J Clin Oncol. 2005 Dec 10;23(35):8932-41
16219933
Cancer Res. 2001 Jul 1;61(13):5262-7
11431368
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):67-71
15093900
Radiother Oncol. 2007 Jun;83(3):389-97
17499868
Clin Cancer Res. 2004 Jul 1;10(13):4464-71
15240538
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Lancet. 2001 Jun 2;357(9270):1728
11403806
JAMA. 2000 Apr 19;283(15):2008-12
10789670
Radiother Oncol. 2006 Jun;79(3):288-97
16730088
Cancer Lett. 2007 Aug 8;253(1):74-88
17320280
Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):161-9
18722267
Clin Cancer Res. 2001 Nov;7(11):3399-403
11705854
Jpn J Clin Oncol. 2007 Nov;37(11):812-9
18057013
Clin Cancer Res. 2002 Aug;8(8):2595-604
12171890
Cancer Res. 2001 Sep 1;61(17):6394-9
11522632